BUSINESS BRIEFING / PHARMACEUTICALS
- Share via
Abbott Laboratories said it would pay $6.6 billion for the pharmaceutical business of Belgian chemicals maker Solvay in a move to further expand internationally and add to its product portfolio.
By buying Brussels-based Solvay, Abbott gains access to emerging markets in Eastern Europe and Asia along with new therapeutic areas, including hormone therapies and vaccines.
Solvay’s flu vaccine Influvac will give Abbott an entrant in the burgeoning vaccines market, which is dominated by European pharmaceutical giants such as GlaxoSmithKline and Novartis.
More to Read
-
Baby formula maker says agreement reached to reopen plant
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
